Recent studies have shown that CD24 correlates with poor prognosis in many types of tumor tissues, including gliomas (Deng et al., 2012), hepatocellular carcinoma (HCC) (Wan et al., 2016), and breast cancer (Jing et al., 2018). This evidence concerns the gene CD24 and neoplasm.